Genmab Updates 2023 Financial Guidance
27 Julho 2023 - 7:01PM
Company Announcement
COPENHAGEN, Denmark;
July 28,
2023 –
Genmab A/S
(Nasdaq:
GMAB) announced
today its preliminary first half
2023 financial results and its
updated 2023 financial
guidance.
Preliminary First Half
2023 Financial Results
In the first half of 2023, Genmab’s revenue increased by 34% and
operating profit increased by 10%, compared to the first half of
2022 primarily due to higher product royalties. Operating expenses
increased by 45%, reflecting continued focused investments in
Genmab’s key priorities.
|
|
First Half |
|
First Half |
|
|
(DKK million) |
|
2023 |
|
2022 |
|
% Increase |
Revenue |
|
7,052 |
|
5,281 |
|
34% |
Operating expenses |
|
(5,118) |
|
(3,520) |
|
45% |
Operating profit |
|
1,934 |
|
1,761 |
|
10% |
Updated 2023 Financial
Guidance
Genmab expects its 2023 revenue to be in the range of DKK 15,500
– 16,500 million, an increase to the previous guidance of DKK
14,600 – 16,100 million, driven by the continued strong growth of
DARZALEX® net sales and higher total royalty revenues from DARZALEX
and other marketed products. DARZALEX royalties are based on
Genmab’s revised estimate of DARZALEX 2023 net sales of USD 9.8 –
10.0 billion compared to Genmab’s previous estimate of USD 9.4 –
10.0 billion.
Genmab anticipates its 2023 operating expenses to be in the
range of DKK 10,400 – 10,900 million, an increase to the previous
guidance of DKK 9,800 – 10,600 million, primarily related to
increased and accelerated investment for epcoritamab clinical
trials and progression of other pipeline products.
Genmab now expects its 2023 operating profit to be in the range
of DKK 4,500 – 6,000 million, compared to the previous guidance of
DKK 3,900 – 6,200 million, driven primarily by the items described
above.
|
|
|
|
|
|
|
Revised |
|
Previous |
(DKK million) |
|
Guidance |
|
Guidance |
Revenue |
|
15,500 - 16,500 |
|
14,600 - 16,100 |
Operating expenses |
|
(10,400) - (10,900) |
|
(9,800) - (10,600) |
Operating profit |
|
4,500 - 6,000* |
|
3,900 - 6,200* |
*Operating profit does not sum due to rounding
Genmab’s full financial results for the first half of 2023 will
be published on August 3, 2023.
About Genmab Genmab is an international
biotechnology company with a core purpose guiding its unstoppable
team to strive towards improving the lives of patients through
innovative and differentiated antibody therapeutics. For more than
20 years, its passionate, innovative and collaborative team has
invented next-generation antibody technology platforms and
leveraged translational research and data sciences, which has
resulted in a proprietary pipeline including bispecific T-cell
engagers, next-generation immune checkpoint modulators, effector
function enhanced antibodies and antibody-drug conjugates. To help
develop and deliver novel antibody therapies to patients, Genmab
has formed 20+ strategic partnerships with biotechnology and
pharmaceutical companies. By 2030, Genmab’s vision is to transform
the lives of people with cancer and other serious diseases with
Knock-Your-Socks-Off (KYSO) antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen,
Denmark with locations in Utrecht, the Netherlands, Princeton, New
Jersey, U.S. and Tokyo, Japan. For more information, please visit
Genmab.com and follow us on Twitter.com/Genmab.
Contact: Marisol
Peron, Senior Vice President, Global Communications & Corporate
AffairsT: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor RelationsT: +45
3377 9558; E: acn@genmab.com This Company Announcement contains
forward looking statements. The words “believe”, “expect”,
“anticipate”, “intend” and “plan” and similar expressions identify
forward looking statements. Actual results or performance may
differ materially from any future results or performance expressed
or implied by such statements. The important factors that could
cause our actual results or performance to differ materially
include, among others, risks associated with pre-clinical and
clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety
issues, uncertainties related to product manufacturing, the lack of
market acceptance of our products, our inability to manage growth,
the competitive environment in relation to our business area and
markets, our inability to attract and retain suitably qualified
personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated
entities, changes and developments in technology which may render
our products or technologies obsolete, and other factors. For a
further discussion of these risks, please refer to the risk
management sections in Genmab’s most recent financial reports,
which are available on www.genmab.com and the risk factors included
in Genmab’s most recent Annual Report on Form 20-F and other
filings with the U.S. Securities and Exchange Commission (SEC),
which are available at www.sec.gov. Genmab does not undertake any
obligation to update or revise forward looking statements in this
Company Announcement nor to confirm such statements to reflect
subsequent events or circumstances after the date made or in
relation to actual results, unless required by law. Genmab A/S
and/or its subsidiaries own the following trademarks: Genmab®; the
Y-shaped Genmab logo®; Genmab in combination with the Y-shaped
Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody® and
HexElect®; DARZALEX® is a trademark of Johnson & Johnson.
Company Announcement no. 36 CVR no. 2102 3884 LEI Code
529900MTJPDPE4MHJ122
Genmab A/S Kalvebod Brygge 43 1560 Copenhagen V Denmark
- 280723_CA36_Updated Guidance
Gen Digital (NASDAQ:GEN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Gen Digital (NASDAQ:GEN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024